Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant pembrolizumab after neoadjuvant chemoimmunotherapy in early triple-negative breast cancer with residual disease
NL-OMON61031Phase 3Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in triple-negative breast cancer (TNBC) comparing Adjuvant pembrolizumab plus standard of care with Standard of care alone (2 arms). Primary endpoint: Invasive disease-free survival. Started Jul 2026; status: recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NL-OMON61031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61031.